Pacira BioSciences Grants Inducement Awards to 14 Employees
Pacira BioSciences announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors without stockholder approval. Four employees received stock options to purchase an aggregate of 58,000 shares of Pacira common stock and 14 employees received restricted stock units for an aggregate of 41,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient's first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $21.02 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on February 1, 2027. Vesting of the equity awards is subject to the employee's continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
Trade with 70% Backtested Accuracy
Analyst Views on PCRX
About PCRX
About the author

- Support for Management Nominees: Institutional Shareholder Services (ISS) recommends that Pacira stockholders vote 'FOR' the management's three director nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance structure and likely enhancing shareholder support for future developments.
- Significant Strategic Execution: Following the implementation of its 5x30 strategy, Pacira has seen measurable performance improvements, indicating that the company's efforts in shareholder value creation are recognized, which may attract more investor interest in its long-term growth potential.
- Board Composition Advantage: ISS emphasizes that Pacira's board consists of highly qualified directors with relevant industry and corporate governance experience, showcasing the company's leadership and strategic direction strengths, which could enhance market trust.
- Opposition to DOMA Nominees: ISS notes that DOMA's nominees lack credibility and fail to present a compelling case for change, which may lead to diminished shareholder confidence in their proposals, thereby solidifying the position of Pacira's current management team.
- Management Nominee Support: Independent proxy advisory firm ISS recommends that Pacira shareholders vote for the three management nominees at the 2026 Annual Meeting, reflecting confidence in the company's governance and strategic direction, which could enhance shareholder trust and boost stock prices.
- Strategic Execution Impact: ISS noted that Pacira's performance has measurably improved following the implementation of its 5x30 shareholder value creation strategy, indicating that the company can effectively navigate market challenges and drive long-term growth under proactive management and board guidance.
- Board Composition Advantage: The Pacira board comprises seven newly appointed or nominated directors with extensive experience in relevant industries and corporate governance, enhancing decision-making capabilities during the company's turnaround phase and increasing shareholder confidence in future prospects.
- Opposition to Dissident Nominees: ISS criticized DOMA's nominees for lacking public company board experience and failing to present a compelling case for change, emphasizing the stability and strategic alignment of Pacira's existing board, which may help maintain operational continuity and market competitiveness.
- Shareholder Voting Recommendation: Glass Lewis has recommended that Pacira shareholders vote in favor of three director nominees at the upcoming Annual Meeting on June 9, 2026, reflecting confidence in the company's strategic direction and likely enhancing shareholder support for governance.
- Shareholder Return Performance: Pacira achieved a total shareholder return of 37% in 2025, with a cumulative return of 23.8% since the launch of the 5x30 strategy, indicating significant progress in enhancing shareholder value and boosting market confidence in its long-term growth potential.
- New Product Pipeline: Pacira's new products, PCRX-201 and PCRX-2002, are in Phase 2 clinical trials and are expected to deliver substantial revenue growth beyond 2030, further solidifying its leadership position in the non-opioid pain management market.
- Intellectual Property Protection: The company has filed 21 Orange Book-listed patents, demonstrating the board's proactive efforts to mitigate future risks, which not only safeguards existing intellectual property but also provides a foundation for future innovation and competitive advantage.
- Shareholder Voting Appeal: Pacira BioSciences urges shareholders to support its three board nominees at the upcoming 2026 Annual Meeting, emphasizing the company's leadership in non-opioid pain therapies and aiming to protect shareholder investments through stable leadership and strategic execution.
- Strong Financial Performance: In 2025, Pacira achieved total revenues of $726.4 million, with GAAP net income of $7 million and non-GAAP net income reaching $122.3 million, demonstrating a more than 31% increase in stock price following the implementation of its 5x30 strategy, indicating a robust recovery in market momentum.
- Expanded Treatment Coverage: In 2025, Pacira's products treated over 2.5 million patients, progressing towards its goal of helping 3 million patients annually by 2030, with EXPAREL achieving a year-over-year growth rate of 6.2%, showcasing the company's sustained growth potential in the non-opioid pain management market.
- Strengthened Intellectual Property Strategy: Pacira reached a favorable settlement with Fresenius Kabi regarding EXPAREL, ensuring exclusivity until 2030, which enhances the company's competitive position in the market, while expanding its patent portfolio to prevent future competition and secure long-term shareholder value creation.
- New Company Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with over 25.2 million shares issued, as CEO emphasized their CXU™ platform's goal to rebuild biological structures, potentially attracting significant investor interest in regenerative medicine.
- Significant Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025, with gross margins at a historic high of 79.4%, reflecting strong demand for its non-opioid pain therapies, which may lead to increased capital inflows into related companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and equivalents with no debt in Q1 2026, and its TrueDent® resins received CE marking, enhancing its penetration in the European market and strengthening the bioprinting industry's infrastructure.
- Wound Care Innovation: Smith & Nephew launched ALLEVYN COMPLETE CARE Foam Dressing in the U.S. in March 2026, targeting chronic wound management with robust scientific backing, addressing the growing global demand for wound care and further expanding the regenerative medicine market.
- New Listing: Conexeu Sciences Inc. debuted on Nasdaq on May 21, 2026, with 25,269,996 shares issued, as CEO emphasized the CXU™ platform's goal to rebuild biological architecture, targeting over 100,000 women annually for breast reconstruction.
- Revenue Growth: Pacira BioSciences achieved total revenue of $726.4 million in 2025 with a GAAP gross margin of 79.4%, reflecting strong market demand for non-opioid pain therapies, which is driving capital back into early-stage regenerative medicine companies.
- Bioprinting Infrastructure: Stratasys reported $237.8 million in cash and short-term deposits with no debt in Q1 2026, and its TrueDent® resins received CE marking, marking a significant advancement in its bioprinting technology in the European market.
- Wound Care Innovation: Smith & Nephew launched the ALLEVYN COMPLETE CARE Foam Dressing in the U.S. on March 10, 2026, addressing the global demand for advanced wound care products, further propelling the commercialization of regenerative medicine.








